Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageOur portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb. The following is a brief description of the Company’s segments: For additional discussion of our reportable segments, see the discussion in Item 1. “Business — Segment Information” and Note 23, “SEGMENT INFORMATION” to our audited Consolidated Financial Statements.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q3 2024 · $2.51BThe company’s own SEC segment disclosure.
- United States and Puerto Rico$1.53B61%
- Other Countries$263.0M10%
- CN$132.0M5%
- CA$104.0M4%
- PL$92.0M4%
- MX$88.0M4%
- Other (8)$296.0M12%
Bausch Health Companies Inc. (BHC) reported revenue of $2.52B in Q1 2026 (quarter ended March 31, 2026), up 12% from the same quarter a year earlier. That came with net loss of $1.43B. For the full year FY2025, revenue was $10.3B (+6.7% year on year) and net income $120M. Its largest region in 2024-Q3 was United Statesand Puerto Rico at $1.53B, 61% of the disclosed total, just ahead of Other Countries at 10%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #20 of 28 by Smart Score